2BO Stock Overview
A biotechnology company, develops drugs to treat neurological diseases and pain.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
Serina Therapeutics, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$5.30 |
52 Week High | US$11.30 |
52 Week Low | US$3.06 |
Beta | 0 |
11 Month Change | -22.63% |
3 Month Change | -24.82% |
1 Year Change | n/a |
33 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -24.82% |
Recent News & Updates
Recent updates
Shareholder Returns
2BO | DE Biotechs | DE Market | |
---|---|---|---|
7D | -28.4% | 4.6% | 3.1% |
1Y | n/a | -13.6% | 13.3% |
Return vs Industry: Insufficient data to determine how 2BO performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how 2BO performed against the German Market.
Price Volatility
2BO volatility | |
---|---|
2BO Average Weekly Movement | 52.0% |
Biotechs Industry Average Movement | 6.2% |
Market Average Movement | 5.0% |
10% most volatile stocks in DE Market | 11.4% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 2BO's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 2BO's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2006 | 10 | Steve Ledger | serinatherapeutics.com |
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson’s disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson’s disease; and SER 228 for the treatment of epilepsy.
Serina Therapeutics, Inc. Fundamentals Summary
2BO fundamental statistics | |
---|---|
Market cap | €53.61m |
Earnings (TTM) | -€6.32m |
Revenue (TTM) | €2.86m |
18.7x
P/S Ratio-8.5x
P/E RatioIs 2BO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
2BO income statement (TTM) | |
---|---|
Revenue | US$3.17m |
Cost of Revenue | US$4.21m |
Gross Profit | -US$1.04m |
Other Expenses | US$5.97m |
Earnings | -US$7.01m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.79 |
Gross Margin | -32.68% |
Net Profit Margin | -220.87% |
Debt/Equity Ratio | -67.9% |
How did 2BO perform over the long term?
See historical performance and comparison